Plant-Derived Analgesics Market Report 2026

The plant-derived analgesics market size has grown strongly in recent years. It will grow from $3.39 billion in 2025 to $3.66 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to traditional medicine adoption, demand for natural pain relief, growth in herbal supplement use, opioid side effect concerns, expansion of botanical extraction.

The plant-derived analgesics market size is expected to see strong growth in the next few years. It will grow to $5.06 billion in 2030 at a compound annual growth rate (CAGR) of 8.4%. The growth in the forecast period can be attributed to rising preference for natural therapeutics, growth in cannabinoid medicines, expansion of plant based drug pipelines, increased clinical validation of botanicals, wider integrative care adoption. Major trends in the forecast period include standardized botanical pain extracts, high purity phytochemical isolation, combination herbal analgesic formulas, enhanced bioavailability plant actives, evidence based botanical therapies.

The growing prevalence of chronic pain conditions is anticipated to drive the growth of the plant-derived analgesics market going forward. Chronic pain conditions refer to long-lasting pain disorders, including musculoskeletal pain, arthritis, neuropathic pain, and inflammatory conditions, that require continuous pain management. The occurrence of chronic pain conditions is increasing worldwide due to aging populations, sedentary lifestyles, rising obesity rates, and the expanding burden of chronic diseases. Plant-derived analgesics support the management of chronic pain conditions by providing pain relief solutions formulated from botanical extracts, herbs, and bioactive plant compounds, which are increasingly utilized as complementary or alternative therapies for pain management. For instance, in November 2024, according to the Centers for Disease Control and Prevention (CDC), a US-based federal public health agency, approximately 24.3% of adults in the United States experienced chronic pain in 2023, while 8.5% reported high-impact chronic pain. Therefore, the increasing prevalence of chronic pain conditions across major healthcare markets is contributing to the growth of the plant-derived analgesics market.

The increasing consumer preference for natural remedies is expected to drive the growth of the plant-derived analgesics market going forward. Natural remedies refer to treatments derived from natural sources such as plants, herbs, minerals, and animal products that are used to prevent, manage, or alleviate health conditions and are commonly associated with traditional, herbal, and complementary medicine practices, often applied as alternatives or adjuncts to conventional medical therapies. The preference for natural remedies is rising mainly due to growing consumer awareness of wellness-focused and plant-based healthcare approaches, along with concerns about the side effects and long-term use of synthetic medicines. Plant-derived analgesics align with this preference by providing pain relief solutions sourced from medicinal plants, addressing consumer demand for plant-based and perceived safer therapeutic options. For instance, in September 2025, according to the American Botanical Council (ABC), a US-based nonprofit educational and research organization, retail sales of herbal dietary supplements in the United States reached a record value of $13.231 billion in 2024. Compared with 2023, US consumers spent an additional $680 million on herbal supplements, representing a year-over-year growth of 5.4%. Therefore, the rising consumer preference for natural remedies is supporting the growth of the plant-derived analgesics market.

Leading companies operating in the plant-derived analgesics market are focusing on technological advancements in botanical extraction, purification, and formulation techniques, including plant-based formulation and bioavailability enhancement, to reduce batch-to-batch variability and improve regulatory and consumer acceptance. Plant-based formulation and bioavailability enhancement refer to the scientific optimization of plant-derived analgesic products using advanced formulation approaches designed to improve the stability, solubility, and absorption of bioactive botanical compounds, supporting more consistent product performance and improved therapeutic delivery. For example, in January 2023, Medterra CBD, LLC., a US-based botanical wellness company, launched its Natural Pain Relief capsules to expand consumer access to plant-based pain management solutions. The Natural Pain Relief capsules are positioned as a plant-based, non-opioid pain management option formulated with standardized botanical ingredients, including turmeric and Levagen+ palmitoylethanolamide (PEA), with the aim of enhancing bioavailability and supporting relief from muscle pain, joint stiffness, and inflammation.

Major companies operating in the plant-derived analgesics market are Dabur India Limited, Patanjali Ayurved Limited, Blackmores Limited, Bionorica SE, Emami Limited, Himalaya Wellness Company, Biologische Heilmittel Heel GmbH, Charak Pharma Private Limited, Indena S.p.A., Nature’s Way Products LLC, Arya Vaidya Sala Kottakkal, Gaia Herbs Farm Inc., Hamdard Laboratories (India), Shree Dhootapapeshwar Limited, Sri Sri Tattva, Euromed S.A., Sami-Sabinsa Group Limited, Martin Bauer Group, Shree Baidyanath Ayurved Bhawan Private Limited, Organic India Private Limited.

Tariffs on botanical raw materials, plant extracts, and specialty formulation inputs are increasing costs in the plant derived analgesics market. Import dependent extract and cannabinoid segments are most affected. Regions relying on cross border herb supply chains face pricing pressure. This can influence finished product affordability. At the same time, tariffs are encouraging local cultivation and domestic botanical processing capacity.

The plant-derived analgesics market research report is one of a series of new reports that provides plant-derived analgesics market statistics, including plant-derived analgesics industry global market size, regional shares, competitors with a plant-derived analgesics market share, detailed plant-derived analgesics market segments, market trends and opportunities, and any further data you may need to thrive in the plant-derived analgesics industry. This plant-derived analgesics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Plant-derived analgesics refer to pain-relieving compounds sourced from natural botanical materials, including medicinal plants containing bioactive ingredients with analgesic properties. These products are developed through extraction, purification, and formulation of plant-based active ingredients to alleviate pain via biological mechanisms such as anti-inflammatory or neuro-modulatory effects. They are widely employed in pharmaceutical, nutraceutical, and traditional medicine applications as alternatives or complements to synthetic pain management therapies.

The key product types of plant-derived analgesics include morphine, codeine, salicin, cannabinoids, and curcumin. Morphine is a plant-derived opioid used for severe pain management, extracted from the opium poppy. These analgesics are available in various formulations, including tablets, capsules, creams, injectables, and oils, and are sourced from plant-derived opioid alkaloids, salicylate-type analgesics, cannabinoids and hemp-derived compounds, polyphenolic compounds, and other phytochemicals. They are distributed through hospitals, clinics, retail outlets, online platforms, and hypermarkets, and are applied across chronic pain management, acute pain relief, post-surgical pain, and neuropathic pain.

The plant-derived analgesics market consists of sales of plant-derived alkaloids and terpenoids, essential oil-based analgesics, capsaicin, menthol, gingerol, and eugenol. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.